<?xml version='1.0' encoding='utf-8'?>
<document id="27485383"><sentence text="Direct and quantitative evaluation of the human CYP3A4 contribution (fm) to drug clearance using the in vitro SILENSOMES model."><entity charOffset="110-120" id="DDI-PubMed.27485383.s1.e0" text="SILENSOMES" /></sentence><sentence text="1" /><sentence text=" Among the different in vitro studies recommended by the regulatory agencies, no gold-standard model can easily and directly measure the quantitative CYP450 contributions to drug biotransformation" /><sentence text=" In this article, we propose an original strategy, called SilensomesTM, to produce human liver microsomes silenced for one specific CYP450, thanks to specific mechanism-based inhibitors (MBI)" /><sentence text=" 2" /><sentence text=" Using azamulin as a specific CYP3A4 MBI, we demonstrated the proof of concept that CYP3A4 can be totally, specifically (even against 3A5) and permanently (at least for six years) inhibited by our process"><entity charOffset="7-15" id="DDI-PubMed.27485383.s6.e0" text="azamulin" /></sentence><sentence text=" Thus, comparing clearance in control and CYP3A4-SilensomesTM, CYP3A4 contributions were determined for 11 CYP3A4 substrates which correlated with known in vivo contributions and revealed accuracy with less than 10% error" /><sentence text=" In comparison, contributions determined using recombinant human CYP450 (rhCYP450s) were less accurate (more than 10% error for 30% of the tested CYP3A4 substrates)" /><sentence text=" 3" /><sentence text=" This easy and ready-to-use in vitro method combines the advantages of existing models (specificity of rhCYP450s and representativeness of HLM) without their drawbacks" /><sentence text=" The same strategy could be used to silence other major CYP450s one-by-one to provide a complete direct CYP450 quantitative phenotyping kit" /><sentence text="" /></document>